

Cover Story
Vitrakvi (larotrectinib) aims to treat a very small group of people—some say fewer than 3,000 new patients a year in the U.S. And since these patients have diseases that span multiple tumor sites, finding them isn't easy.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Trump backs off the 100% pharma tariffs ultimatum
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Latinx oncology leaders talk about the impact of federal policy on cancer outcomes in Latinx communities
- ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology
- The insinuation that AstroTurf causes GBM has no basis in science
The Philadelphia Inquirer series does disservice to brain tumor community - Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research